Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board

NHS

High Cost Drugs

This page contains guidance issued by the GMMMG High Cost Drugs Subgroup. If you are an NHS healthcare professional working within the GM region and wish to submit information for consideration by the group please contact the professional secretary of the group via email

 

Documents

Date

Review Date

PDF document 

Free of charge (FOC) medicines schemes

Nov 2018

 

MS Excel document 

Enabled Blueteq List

Oct 2018

updated monthly

MS Excel document 

GMMMG PBR Ex Drugs final 2017-19

Apr 2018

Apr 2019

MS Word document 

GMMMG PBR Exclusions supporting information 17-19

Apr 2018

Apr 2019

MS Excel document 

PBR Ex Devices list 2017-19

Jan 2017

Apr 2019

PDF document 

Commissioning framework for biologic medicines: defining best value

Jun 2018

To be reviewed if national or
GMMMG guidance changes

PDF document 

Position Statement for funding of High Cost Drugs when patients transition from Children or adolescent services to adult services

Oct 2017

To be reviewed if national or
GMMMG guidance changes

PDF document 

Position statement for using biologic therapies to treat adult patients with Juvenile Idiopathic Arthritis (JIA)

Oct 2017

To be reviewed if national or
GMMMG guidance changes

PDF document 

Implementation and principles of a Greater Manchester biosimilar gainshare agreement

Jul 2017

To be reviewed if national or
GMMMG guidance changes

PDF document 

Rituximab Biosimilar Uptake Recommendation

Jul 2017

To be reviewed if national or
GMMMG guidance changes

PDF document 

Prescribing of high cost biosimilar biological medicines

Jul 2016

To be reviewed if national or
GMMMG guidance changes

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer